Corey L Snyder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Corey L Snyder has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Martina Lee Porter
Beth Israel Deaconess Medical Center, Department of Dermatology, Harvard Medical School, Boston, USA
3 shared publications - Alexandra Boer Kimball
Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin, Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
2 shared publications - Ruby S. Gibson
Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center Boston Massachusetts USA
2 shared publications - Anusha Kumar
Stanford University School of Medicine
1 shared publication - Sophio Kirimlishvili
Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center , Boston, MA
1 shared publication - Stella X. Chen
Department of Dermatology, Mayo Clinic, Scottsdale, USA
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (5) , 1010-1013
Validation of a morphological hidradenitis suppurativa phenotype algorithm (HS-KAPPA)
HS-KAPPA, an accessible hidradenitis suppurativa (HS) phenotype algorithm, was developed to reliably categorize patients with HS based on morphology. We validated HS-KAPPA with a reproducible training module. HS-KAPPA could be helpful in clinical practice and in clinical trials.
- 12 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (5) , 1010-1013
Open AccessValidation of a morphological hidradenitis suppurativa phenotype algorithm (HS-KAPPA)
HS-KAPPA, an accessible hidradenitis suppurativa (HS) phenotype algorithm, was developed to reliably categorize patients with HS based on morphology. We validated HS-KAPPA with a reproducible training module. HS-KAPPA could be helpful in clinical practice and in clinical trials.
- 16 October 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (17) , 1449-1457
Secukinumab in the Treatment of Hidradenitis Suppurativa
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflamm... Plain language summary Hidradenitis suppurativa is a chronic skin disorder characterized by recurrent painful bumps, tunnels underneath the skin and significant scarring. To date, the only US FDA-a... Tweetable abstract Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. We review its role in the treatment of hidradenitis suppurativa (HS).
- 16 October 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (17) , 1449-1457
Secukinumab in the Treatment of Hidradenitis Suppurativa
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflamm... Plain language summary Hidradenitis suppurativa is a chronic skin disorder characterized by recurrent painful bumps, tunnels underneath the skin and significant scarring. To date, the only US FDA-a... Tweetable abstract Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. We review its role in the treatment of hidradenitis suppurativa (HS).
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1833-1841
Obstacles to Early Diagnosis and Treatment of Hidradenitis Suppurativa: Current Perspectives on Improving Clinical Management
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can progress to significant tunnels and scars that affect quality of life, especially if diagnosis and treatment are delayed. Average delay after initial presentation of HS symptoms can range from 3 to 10 years in adults and 1 to 2 years in children. Factors associated with diagnostic delay include female gender, non-white race, and greater disease severity at diagnosis. Contributing factors include misdiagnoses, difficulty accessing a dermatologist, hesitation in seeking care due to the stigmatizing nature of the disease, and lack of awareness among providers and patients. While efforts to increase awareness include academic talks at conferences and by foundations geared toward HS, social media offers the opportunity to reach young audiences. Many patients report dissatisfaction with their HS treatments. Better understanding of HS pathophysiology and implementation of clinically focused phenotypes and endotypes can lead to development of more targeted and efficacious therapies. FDA approval of medications for HS beyond adalimumab will increase access to a wider selection of therapies, and implementation of therapeutic drug monitoring may maximize the use of biologics for HS.
- 1 July 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 1833-1841
Open AccessObstacles to Early Diagnosis and Treatment of Hidradenitis Suppurativa: Current Perspectives on Improving Clinical Management
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can progress to significant tunnels and scars that affect quality of life, especially if diagnosis and treatment are delayed. Average delay after initial presentation of HS symptoms can range from 3 to 10 years in adults and 1 to 2 years in children. Factors associated with diagnostic delay include female gender, non-white race, and greater disease severity at diagnosis. Contributing factors include misdiagnoses, difficulty accessing a dermatologist, hesitation in seeking care due to the stigmatizing nature of the disease, and lack of awareness among providers and patients. While efforts to increase awareness include academic talks at conferences and by foundations geared toward HS, social media offers the opportunity to reach young audiences. Many patients report dissatisfaction with their HS treatments. Better understanding of HS pathophysiology and implementation of clinically focused phenotypes and endotypes can lead to development of more targeted and efficacious therapies. FDA approval of medications for HS beyond adalimumab will increase access to a wider selection of therapies, and implementation of therapeutic drug monitoring may maximize the use of biologics for HS.